Amneal Pharmaceuticals, Inc Class A Common Stock

Yahoo Finance • 17 days ago

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasd... Full story

Yahoo Finance • 21 days ago

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided a longer duration of benefit with each dose... Full story

Yahoo Finance • 24 days ago

Amneal to Participate in Upcoming Investor Conferences

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in follo... Full story

Yahoo Finance • 25 days ago

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026 BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“... Full story

Yahoo Finance • last month

Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs

Key Points The option-exercise sale represented a notable amount of Shah's overall holdings. Nevertheless, the executive’s remaining stake—about 146,000 shares—still represents meaningful exposure. For long-term investors, Amneal’s growin... Full story

Yahoo Finance • last month

Amneal Secures FDA Approval For First Generic Version Of Omnipaque Injection

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. Food and Drug Administration has approved its iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque injection. Iohexol is a rad... Full story

Yahoo Finance • last month

Amneal Receives U.S. FDA Approval for Iohexol Injection

BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s iohexol injection (300 mg... Full story

Yahoo Finance • 2 months ago

Amneal raises 2025 EPS guidance and outlines $300M–$500M CREXONT sales target as portfolio expansion accelerates

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q3 2025 MANAGEMENT VIEW * Chirag Patel, Co-Founder and Co-CEO, stated the company is "pleased with our strong third quarter performance, which represents another consecutive quarter... Full story

Yahoo Finance • 2 months ago

Amneal Reports Third Quarter 2025 Financial Results

‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER, N.J., Oct. 30... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: * Altria Group (MO [https://seekingalpha.com/symbol/MO]) * Merck & Co. (MRK [https://seekingalpha.com/symbol/MRK]) * Enterprise Products Partners L.P. (EPD [https://seekin... Full story

Yahoo Finance • 2 months ago

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal P... Full story

Yahoo Finance • 2 months ago

Trump administration prepares probe targeting global drug pricing — FT

[Visiting Australian Prime Minister Anthony Albanese Meets With Trump At The White House] Kevin Dietsch/Getty Images News The Trump administration is preparing to launch a new investigation under Section 301 of the Trade Act of 1974 to de... Full story

Yahoo Finance • 3 months ago

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Biosimilar XOLAIR FDA Submission – Learn Why

Amneal Pharmaceuticals recently announced the submission of a Biologics License Application to the U.S. FDA for a proposed biosimilar to XOLAIR®, a leading therapy with approximately US$4.1 billion in annual U.S. sales, and will present at... Full story

Yahoo Finance • 3 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Amneal Pharmaceuticals, Inc. is one of them. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) continues to strengthen its position in generic, branded, and spe... Full story

Yahoo Finance • 3 months ago

Amneal to Report Third Quarter 2025 Results on October 30, 2025

BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 finan... Full story

Yahoo Finance • 3 months ago

Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis

[US Food and Drug Administration (FDA)] * Amneal Pharmaceuticals (NASDAQ:AMRX [https://seekingalpha.com/symbol/AMRX]) on Friday announced the FDA submissions to seek U.S. approval for an off-patent version of Xolair, an asthma therapy m... Full story

Yahoo Finance • 3 months ago

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

BRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administratio... Full story

Yahoo Finance • 3 months ago

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Amneal Pharmaceuticals LLC Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segment BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“... Full story

Yahoo Finance • 3 months ago

Amneal wins FDA nod for generic targeting Jazz Pharma’s Xyrem

[FDA Seal of Approval and Rubber Stamp] asbe/iStock via Getty Images Amneal Pharmaceuticals (NASDAQ:AMRX [https://seekingalpha.com/symbol/AMRX]) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its generic p... Full story

Yahoo Finance • 4 months ago

Amneal gets FDA nod for generic version of Risperdal Consta

[Anatomical 3D illustration of the transparent human head interior.] AntonioGuillem/iStock via Getty Images * Amneal Pharmaceuticals (NASDAQ:AMRX [https://seekingalpha.com/symbol/AMRX]) has received approval from the U.S. FDA for its an... Full story